This insight suggests that pharmacological interventions aimed at stabilizing the MVK protein could offer potential therapeutic avenues for the treatment of MKD, especially for patients with severe forms such as mevalonic aciduria (MA) (12). The gene discussed is MVK; the disease is mevalonic aciduria.